Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Rating) shares were up 3.7% during trading on Friday . The stock traded as high as $7.79 and last traded at $7.79. Approximately 651 shares changed hands during trading, a decline of 100% from the average daily volume of 237,348 shares. The stock had previously closed at $7.51.
Analyst Ratings Changes
Several research analysts have recently commented on TNGX shares. Wedbush raised their price target on Tango Therapeutics to $21.00 in a research report on Wednesday, November 16th. HC Wainwright upgraded Tango Therapeutics from a "neutral" rating to a "buy" rating in a research note on Thursday, October 20th.
Get Tango Therapeutics alerts:Tango Therapeutics Price Performance
The company has a market capitalization of $690.45 million, a price-to-earnings ratio of -6.81 and a beta of 1.85. The stock has a 50 day simple moving average of $7.58 and a two-hundred day simple moving average of $5.46.
Insider Buying and Selling at Tango Therapeutics
In other Tango Therapeutics news, major shareholder Boxer Capital, Llc purchased 70,394 shares of the business's stock in a transaction on Thursday, October 6th. The shares were bought at an average cost of $4.06 per share, for a total transaction of $285,799.64. Following the completion of the purchase, the insider now directly owns 7,053,642 shares in the company, valued at $28,637,786.52. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 283,000 shares of company stock worth $1,202,524 over the last ninety days. Corporate insiders own 3.70% of the company's stock.Institutional Trading of Tango Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in TNGX. Alaethes Wealth LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $91,000. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth about $78,000. Ensign Peak Advisors Inc grew its holdings in shares of Tango Therapeutics by 183.4% during the second quarter. Ensign Peak Advisors Inc now owns 299,391 shares of the company's stock worth $1,356,000 after buying an additional 193,735 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics during the first quarter worth about $113,000. Finally, FMR LLC grew its holdings in shares of Tango Therapeutics by 11.0% during the second quarter. FMR LLC now owns 7,631,917 shares of the company's stock worth $34,572,000 after buying an additional 755,942 shares during the last quarter. Institutional investors and hedge funds own 77.30% of the company's stock.
Tango Therapeutics Company Profile
(Get Rating)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
- Get a free copy of the StockNews.com research report on Tango Therapeutics (TNGX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.